EUVIMEDObjevte EUVIMED
CrossrefInformační karta

Retrospective Evaluation of the Quick Sequential Organ Failure Assessment (qSOFA) Score as a Prognostic Indicator in Dogs With Systemic Inflammatory Response Syndrome (2017–2023): 112 Cases

Dongseok Kim, Jin‐Kyung Kim, Hana Kim, Sungin Lee, Won‐Jae Lee, Sung‐Ho Yun, Min Jang

Journal of Veterinary Emergency and Critical Care · 2026-11-09

DOI: 10.1111/vec.70177 ↗
AbstraktBibliografické údaje

Abstrakt

ABSTRACT Objective To evaluate the prognostic value of the quick Sequential Organ Failure Assessment (qSOFA) score in dogs meeting the systemic inflammatory response syndrome (SIRS) criteria. Design Retrospective study. Setting Secondary referral animal hospital. Animals A total of 112 dogs diagnosed with SIRS between 2017 and 2023 were included. Interventions None. Measurements and Main Results A total of 112 dogs meeting the SIRS criteria were included; of these, 65 (60%) died during hospitalization. In the univariable analysis, a qSOFA score ≥2 was associated with mortality ( p < 0.001). In the multivariable logistic regression analysis, qSOFA score ≥2 was not retained as an independent predictor of mortality after adjustment for other variables (odds ratio [OR]: 2.24, 95% CI: 0.71–7.06; p = 0.172). Receiver operating characteristic (ROC) curve analysis for qSOFA score ≥2 yielded an area under the curve (AUC) of 0.73 (95% CI: 0.63–0.84), with a sensitivity of 72% and a specificity of 75% for predicting mortality. Conclusion In dogs with SIRS, the qSOFA score may serve as a practical tool for initial risk stratification. Nevertheless, given its limited prognostic value when used independently, further study is warranted.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →